+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Alzheimer's Disease Diagnostics and Therapeutics Market - Growth, Trends, and Forecast (2020-2025)

  • ID: 4591925
  • Report
  • May 2020
  • Region: Global
  • 114 pages
  • Mordor Intelligence
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now


  • Allergan PLC?
  • Biogen Inc
  • Eisai Co. Ltd
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • MORE
The global Alzheimer’s disease diagnostics and therapeutics market has been found witnessing a CAGR of 6.7%. The key factors propelling the growth of this market are increasing prevalence of chronic diseases like dementia, increasing pipeline drug development, investment in biomarkers for drug development and increasing sophisticated diagnostics for early detection and more precise drug development.

Alzheimer’s disease is one of the most prevalent types of dementia that occurs worldwide. According to the Alzheimer’s net, there are nearly 50 million people that have Alzheimer’s or related dementia. The development of clinical diagnostics and therapeutics for Alzheimer's disease (AD) and other neurodegenerative conditions is becoming very important. So, certain biomarkers that may improve the accuracy of the diagnosis are used.

Investing in biomarkers for drug development and early detection of AD acts as a major driver, and fuels the growth of the Alzheimer's disease diagnostics and therapeutics market, globally.

Key Market Trends

Cholinesterase Inhibitors are Expected to Hold the Highest Market Share in the Therapeutics Segment

Cholinesterase inhibitors are believed to have the largest market size and are expected to witness a high CAGR, during the forecast period. Cholinesterase inhibitors are used for the treatment of Alzheimer’s. These cholinesterase inhibitors are approved by the US FDA. Most physicians and perhaps most patients consider cholinergic drugs.

Donepezil, galantamine, and rivastigmine are the generic names of cholinesterase inhibitors, which are likely to be the first-line pharmacotherapy choice for mild to moderate Alzheimer’s disease. These drugs have somewhat different pharmacological properties, but all of them work by the same mechanism, which involves inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase.

Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Hence, owing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics ,and is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer’s disease diagnostics and therapeutics market. According to the Alzheimer’s Association, more than 5 million Americans suffer from Alzheimer’s, as of 2017.

The United States is considered to be the global leader in Alzheimer’s disease intervention and management. America has a large pool of biopharmaceutical companies, which cumulatively have 85 drugs for combating Alzheimer’s disease in various stages of the pipeline. Hence, the market is expected to register a healthy CAGR over the forecast period.

Competitive Landscape

The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., hold a substantial market share in the Alzheimer’s disease diagnostics and therapeutics market.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Note: Product cover images may vary from those shown
2 of 5


  • Allergan PLC?
  • Biogen Inc
  • Eisai Co. Ltd
  • Eli Lilly & Company
  • F. Hoffmann-La Roche
  • Johnson & Johnson
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Use of Biomarkers in Diagnosis and Drug Development
4.2.2 Large Number of Drugs in Pipeline​
4.2.3 Emerging Novel Diagnostic Technologies​
4.3 Market Restraints
4.3.1 High Failure Rates of Late-stage Drugs
4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis​
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry

5.1 By Therapeutics
5.1.1 Cholinesterase Inhibitors
5.1.2 NMDA Receptor Antagonists
5.1.3 Other Therapeutics
5.2 By Diagnostics
5.2.1 Brain Imaging
5.2.2 CFS Test for Alzheimer's Disease
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche
6.1.2 Novartis AG
6.1.3 Merck & Co. Inc
6.1.4 Pfizer Inc
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly & Company
6.1.9 Lupin Limited
6.1.10 Allergan PLC​

Note: Product cover images may vary from those shown
3 of 5


4 of 5
  • F. Hoffmann-La Roche
  • Novartis AG
  • Merck & Co. Inc
  • Pfizer Inc
  • Eisai Co. Ltd
  • Biogen Inc
  • Johnson & Johnson
  • Eli Lilly & Company
  • Lupin Limited
  • Allergan PLC​
Note: Product cover images may vary from those shown
5 of 5